BioCentury | Oct 7, 2020
Product Development

Oct. 6 Quick Takes: BARDA whistleblower quits NIH; plus COVID-19 updates from Vir-GSK, BioNTech, Pfizer, $115M B round for Talaris and more

Former BARDA Director Bright leaving NIH Rick Bright, the former director of the Biomedical Advanced Research and Development Authority and HHS deputy assistant secretary for preparedness and response, has resigned from NIH, according to a...
BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

As partnerships aimed at preventing COVID-19 or treating early disease continue to form and expand, CSL has begun testing a blood coagulation factor inhibitor for severe COVID-19. The CSL Behring unit of CSL Ltd. (ASX:CSL)...
BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

A slew of therapies entered the clinic this week aimed at tamping down the immune system to treat excessive lung inflammation in COVID-19 patients, even as BARDA announced it would no longer fund the class...
BioCentury | Jun 2, 2020
Product Development

Phase I start marks first for anti-SARS-CoV-2 mAbs, first for AbCellera

A COVID-19 mAb from Eli Lilly and AbCellera has become the first against the virus to start human trials and is also the Vancouver-based company’s first product to enter the clinic. While the Phase I...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

ChemoCentryx therapy fails Phase II study in rare renal disorder ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study...
BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

Editas Medicine Inc. (NASDAQ:EDIT) disclosed in an SEC filing that Judith Abrams resigned as CMO. The gene editing company did not immediately respond to a request for comment on its succession plans for the post....
BioCentury | Mar 17, 2020
Product Development

Phase II data bring Blueprint closer to major market expansion for Ayvakit

With positive initial data for Ayvakit in indolent systemic mastocytosis, Blueprint is moving into position to expand its only approved drug into a much larger patient population while sticking to its strategy of focusing on...
BioCentury | Oct 8, 2019
Company News

Oct. 8 Company Quick Takes: Novartis’ anti-VEGF approved for AMD; plus Merck-4D, Acorda, Clinuvel and Puma

Novartis’ Eylea competitor approved FDA approved Beovu brolucizumab-dbll from Novartis AG (NYSE:NVS; SIX:NOVN) to treat wet age-related macular degeneration. In the Phase III HAWK and HARRIER trials, the anti-VEGF single-chain antibody fragment led to vision...
BioCentury | Aug 7, 2019
Clinical News

Rhythm data set up submissions for ultra-rare obesity disorders

Two new Phase III readouts pave the way for Rhythm Pharmaceuticals to make its first regulatory submissions for setmelanotide to treat rare genetic disorders that result in obesity. Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Wednesday that...
BioCentury | Jul 25, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2019

New Therapeutic Targets and Biomarkers: June 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in June. Therapeutic targets are defined as any protein, gene or other molecule...
Items per page:
1 - 10 of 510